CoChat
Sign Up
Cited by 98Peroxisome Proliferator-Activated ReceptorsParaoxonase enzyme and polymorphismsCardiovascular Disease and Adiposity

Beneficial Vascular and Metabolic Effects of Peroxisome Proliferator-Activated Receptor-α Activators

Han, Seung Hwan, Quon, Michael J., Koh, Kwang Kon·2005·Hypertension
DOI 10.1161/01.hyp.0000187900.36455.4c
Open this paper in CoChat — free account

Abstract

Fibric acid is a synthetic ligand of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-α that is highly expressed in skeletal muscle and heart, where it promotes β-oxidation of fatty acids to mediate hypolipidemic actions. PPAR-α regulates expression of key proteins involved in atherogenesis, vascular inflammation, plaque instability, and thrombosis. Thus, PPAR-α may exert direct antiatherogenic actions in the vascular wall. Endothelial dysfunction associated with the metabolic syndrome and other insulin-resistant states is characterized by impaired insulin-stimulated nitric oxide production from the endothelium and decreased blood flow to skeletal muscle. Thus, improvement in insulin sensitivity leads to improved endothelial function. This may be an additional mechanism whereby fibrates decrease the incidence of coronary heart disease. Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. In this review, we discuss the mechanisms underlying the vascular and metabolic effects of fibrates that may act synergistically to prevent or regress atherosclerosis and coronary heart disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.hyp.0000187900.36455.4c

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other studies suggest that fenofibrate has anti-inflammatory effects with reduction of inflammatory cytokines, which may also have beneficial effects on the kidney.

    “Other studies suggest that fenofibrate has anti-inflammatory effects with reduction of inflammatory cytokines, which may also have beneficial effects on the kidney.27”

    From Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes (2019) · cites this paper as [27]

    The Effects on Inflammation section reports that fenofibrate lowered TNF-α levels and reduced IL-1β expression or release, supporting the claim about anti-inflammatory effects and cytokines. The Effects on Vasomotor Function section mentions renal tubules in connection with blood-pressure lowering, but the paper does not link cytokine reduction to a potential kidney benefit. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 69 · Cited by 98

Research works printed but not linked: 60

  1. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046 -1051.
  2. Koh KK. Effects of statins on vascular wall: vasomotor function, inflam- mation, and plaque stability. Cardiovasc Res. 2000;47:648 -657.
  3. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol. 2000;76:21-30.
  4. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002;22:717-726.
  5. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
  6. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endo- thelium. Curr Diabetes Rep. 2003;3:279 -288.
  7. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y; Osaka CAD Study Group. Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23:85-89.
  8. Heilbronn LK, Smith SR, Ravussin E. The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des. 2003;9:1411-1418.
  9. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adi- ponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021-45026.
  10. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
  11. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipi- daemia and future perspectives. Atherosclerosis. 2003;171:1-13.
  12. Koh KK, Ahn JY, Han SH, Jin DK, Kim HS, Lee KC, Shin EK, Sakuma I. Effects of fenofibrate on lipoproteins, vasomotor function, and sero- logical markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis. 2004;174:379 -383.
  13. Koh KK, Han SH, Quon MJ, Ahn JY, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care. 2005;28:1419 -1424.
  14. Devroey D, Velkeniers B, Duquet W, Betz W. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins.' Int J Cardiol. 2005; 101:231-235.
  15. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Seo YH, Choi IS, Shin EK. Additive beneficial effects of fenofibrate combined with atorvastatin in treatment of combined hyperlipidemia. J Am Coll Cardiol. 2005;45: 1649 -1653.
  16. Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996;7:843-850.
  17. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002;25:1198 -1202.
  18. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 2003;91:956 -960.
  19. Mantel-Teeuwisse AK, Klungel OH, Herings RM, van Puijenbroek EP, Porsius AJ, de Boer A. Myopathy due to statin/fibrate use in the Neth- erlands. Ann Pharmacother. 2002;36:1957-1960.
  20. Taher TH, Dzavik V, Reteff EM, Pearson GJ, Woloschuk BL, Francis GA. Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. Am J Cardiol. 2002;89:390 -394.
  21. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomy- olysis. N Engl J Med. 2002;346:539 -540.
  22. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. Mechanistic studies on metabolic inter- actions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002; 301:1042-1051.
  23. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol. 2005;95: 462-468.
  24. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxi- dative stress in type 2 diabetes mellitus. Circulation. 2000;101: 1773-1779.
  25. Wilmink HW, Twickler MB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, Rabelink TJ, Stroes ES. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Car- diovasc Res. 2001;50:577-582.
  26. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angio- graphically normal and stenotic coronary arteries improves after choles- terol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995; 26:1615-1622.
  27. Andrews TC, Whitney EJ, Green G, Kalenian R, Personius BE. Effect of gemfibrozil ϩ/-niacin ϩ/-cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels Ͻ160 mg/dl and high-density lipoprotein cholesterol levels Ͻ40 mg/dl. Am J Cardiol. 1997;80:831-835.
  28. Marchesi S, Lupattelli G, Lombardini R, Roscini AR, Siepi D, Vaudo G, Pirro M, Sinzinger H, Schillaci G, Mannarino E. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther. 2003;28:419 -424.
  29. Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high- density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144: 165-172.
  30. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL. PPAR-␣ activator effects on Ang II-induced vascular oxi- dative stress and inflammation. Hypertension. 2002;40:866 -871.
  31. Colville-Nash PR, Qureshi SS, Willis D, Willoughby DA. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J Immunol. 1998;161:978 -984.
  32. Tabernero A, Schoonjans K, Jesel L, Carpusca I, Auwerx J, Andriantsitohaina R. Activation of the peroxisome proliferator-activated receptor-␣ protects against myocardial ischaemic injury and improves endothelial vasodilatation. BMC Pharmacol. 2002;2:10.
  33. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor-␣ activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264 -6271.
  34. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE. Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension. 2005;45:730 -735.
  35. Ogata T, Miyauchi T, Sakai S, Takanashi M, Irukayama-Tomobe Y, Yamaguchi I. Myocardial fibrosis and diastolic dysfunction in deoxycor- ticosterone acetate-salt hypertensive rats is ameliorated by the per- oxisome proliferator-activated receptor-␣ activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-B pathway. J Am Coll Cardiol. 2004;43:1481-1488.
  36. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92:1866 -1874.
  37. Koh KK, Han SH, Quon MJ. Role of inflammatory markers in cardio- vascular diseases related to the metabolic syndrome: insights from ther- apeutic interventions. J Am Coll Cardiol. 2005 In press.
  38. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR-␣ activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125-3131.
  39. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation. 2001; 103:2531-2534.
  40. Kowalski J, Okopien B, Madej A, Zielinski M, Belowski D, Kalina Z, Herman ZS. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther. 2003;41:241-247.
  41. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HM, Kooistra T. Evidence for anti-inflammatory activity of statins and PPAR-␣ activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004;103:4188 -4194.
  42. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants and small dense LDL and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. J Atheroscler Thromb. 2004;11:278 -285.
  43. Ye P, Fang H, Zhou X, He YL, Liu YX. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-␣ expression in neonatal rat cardiac myocytes. Chin Med Sci J. 2004;19: 243-247.
  44. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Acti- vation of human aortic smooth-muscle cells is inhibited by PPAR-␣ but, not by PPAR-␥ activators. Nature. 1998;393:790 -793.
  45. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
  46. Okopien B, Huzarska M, Kulach A, Stachura-Kulach A, Madej A, Belowski D, Zielinski M, Herman ZS. Hypolipidemic drugs affect monocyte IL-1␤ gene expression and release in patients with IIa and IIb dyslipidemia. J Cardiovasc Pharmacol. 2005;45:160 -164.
  47. Scho ¨nbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
  48. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull. 2004;27:1537-1543.
  49. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, Shiomi M, Aikawa M. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlip- idemic rabbits. Circulation. 2001;103:993-999.
  50. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993-998.
  51. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPAR-␥: differentiation-dependent peroxisomal proliferator-activated receptor-␥ (PPAR-␥) expression and reduction of MMP-9 activity through PPAR-␥ activation in mononuclear phagocytes in vitro. Am J Pathol. 1998;153:17-23.
  52. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions human atherosclerotic plaques. J Clin Invest. 1994;94: 2493-2503.
  53. Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPAR-␣ agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation. 2001;103:207-212.
  54. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis. 1998;138:217-225.
  55. Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S. The beneficial effects of lipid-lowering drugs beyond lipid- lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia. Metab- olism. 2005;54:677-681.
  56. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR-␣, PPAR-␥, and LXR. Biochem Biophys Res Commun. 2004;314:151-158.
  57. Shimomura K, Shimizu H, Ikeda M, Okada S, Kakei M, Matsumoto S, Mori M. Fenofibrate, troglitazone, and 15-deoxy-⌬12,14-prostaglandin J2 close K ATP channels and induce insulin secretion. J Pharmacol Exp Ther. 2004;310:1273-1280.
  58. Idzior-Walus B, Sieradzki J, Rostworowski W, Zdzienicka A, Kawalec E, Wojcik J, Zarnecki A, Blane G. Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. Eur J Clin Invest. 2000;30:871-878.
  59. Koh KK, Quon MJ, Han SH, Chung W-J, Ahn JY, Seo Y-H, Kang MH, Ahn TH, Choi IS, Shin EK. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004;110:3697-3692.
  60. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-␣: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.

Authors
Han, S. H., Quon, M. J., & Koh, K. K.
Affiliations
National Center for Complementary and Integrative Health (US)
ORCID
Venue
Hypertension
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-11
Volume
46
Issue
5
Pages
1086-1092
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
DOI
10.1161/01.hyp.0000187900.36455.4c
OpenAlex
W2121098010
Cited by
98
References
69
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 4 · 2018: 4 · 2016: 4 · 2015: 3 · 2014: 3 · 2013: 7 · 2012: 10
FWCI
1.00
Type
journal article
Language
en
Open access
closed
Locations
  • Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
fibrates, atherosclerosis, coronary artery disease, endothelial dysfunction, insulin resistance, metabolic syndrome, adiponectin, insulin sensitivity, nitric oxide, fatty acid beta-oxidation, vascular inflammation, thrombosis, plaque vulnerability
MeSH terms
Cardiotonic Agents, Cardiovascular Diseases, Clofibric Acid, Coronary Disease, Humans, Lipoproteins, Risk Factors, PPAR alpha, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review